caused anemia Hepatitis B vaccine Antifibrinolytic drugs such as tranexamic acid or ε-aminocaproic acid (Amicar) Desmopressin (DDAVP) does not normalize the bleeding time in Glanzmann's thrombasthenia but anecdotally improves hemostasis Hormonal contraceptives to control excessive menstrual bleeding Topical agents such as gelfoam, fibrin sealants, polyethylene glycol polymers, custom dental splints Platelet transfusions (only if bleeding is severe; risk of platelet alloimmunization) Recombinant factor VIIa, AryoSeven or NovoSeven FDA approved this drug for the treatment of the disease in July 2014. Hematopoietic stem cell transplantation (HSCT) for severe recurrent hemorrhages Eponym It is named after Eduard Glanzmann (1887-1959), the Swiss pediatrician who originally described it. History The subsequent studies, following Eduard Glanzmann's description of hemorrhagic symptoms and "weak platelets" demonstrated that these patients have prolonged bleeding times and their platelets failed to aggregate in response to activation. In the mid-1970s, Nurden and Caen and Phillips and colleagues discovered that thrombasthenic platelets are deficient in integrins αIIbβ3. See also Platelet Coagulation Bernard-Soulier syndrome References External links Autosomal recessive disorders Coagulopathies Rare diseases